Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02732704 · ClinicalTrials.gov registry record · NA

THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

A NA study of Aortic Regurgitation, sponsored by JenaValve Technology.

Active
Registry status
NA
Development phase
100
Enrollment target
19
Study locations

NCT02732704: Active NA study of Aortic Regurgitation, sponsored by JenaValve Technology.

NCT02732704 is a NA study of Aortic Regurgitation that is active but no longer recruiting, run by JenaValve Technology. The registered enrollment target is 100 participants, below the 279-participant average among 6 other Aortic Regurgitation trials with a reported enrollment target (64% lower). The trial reports 19 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02732704, a NA study of Aortic Regurgitation, is active but no longer recruiting, sponsored by JenaValve Technology.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
19
Study locations

Study Summary

To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.

Primary Outcome

All-Cause mortality within the first 30 days post index procedure

Conditions Studied

Interventions

  • DEVICE JenaValve Pericardial TAVR System

Study Locations (19)

Other

  • Kerckhoff-Klinik GmbH Bad Nauheim - Bad Nauheim
  • Herz- und Diabeteszentrum NRW Ruhr-Universität Bochum Bad Oeynhausen - Bad Oeynhausen
  • Deutsches Herzzentrum Berlin - Berlin
  • Universitätsklinikum Bonn - Bonn
  • Herzzentrum der Universität zu Köln - Cologne
  • Universitätsklinikum Frankfurt - Frankfurt
  • Universitäres Herzzentrum Hamburg - Hamburg
  • Leiden University Medical Center - Leiden
  • St. Antonius Hospital - Nieuwegein
  • Erasmus University Medical Center - Rotterdam

California

  • Cedars Sinai Medical Center - Los Angeles
  • California Pacific Medical Center Research Institute - San Francisco

Georgia

  • Piedmont Healthcare - Atlanta
  • Emory University Hospital - Atlanta

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Michigan

  • University of Michigan - Ann Arbor

New York

  • New York-Presbyterian/ Columbia University Medical Center - New York

Texas

  • Baylor Scott & White Research Institute - Dallas

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2018-04-20
Est. Completion 2027-09-29
Phase NA
JenaValve Technology

4 total trials

What the registry record for NCT02732704 still lists

NCT02732704 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 279-participant average among 6 other Aortic Regurgitation trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Aortic Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which JenaValve Pericardial TAVR System is the first listed.

NCT02732704 lists 19 locations in 8 states (Other, California, Georgia).

Frequently Asked Questions

What is clinical trial NCT02732704 about?

NCT02732704 is a clinical study titled "THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study". To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgita...

What is the current status of trial NCT02732704?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-04-20. Estimated completion is 2027-09-29.

What conditions does trial NCT02732704 study?

This clinical trial studies the following conditions: Aortic Regurgitation.

What interventions are being tested in trial NCT02732704?

The interventions under investigation include: JenaValve Pericardial TAVR System (DEVICE).

Who is sponsoring clinical trial NCT02732704?

This trial is sponsored by JenaValve Technology, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02732704 being conducted?

This trial has 19 study locations across California, District of Columbia, Georgia, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Regurgitation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02732704, the US trial registry maintained by the National Library of Medicine. NCT02732704 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.